Aetion, a tech startup focused on real-world evidence in healthcare, announced plans to buy synthetic real-world data company Replica Analytics for an undisclosed sum.
This news comes less than a year after Aetion announced a $110 million Series C funding round led by Warburg Pincus.
“Replica is a pioneer in [synthetic data generation software], and this means that they are creating privacy-protected, synthetic copies of real-world data while preserving the statistical integrity and utility of the original data, which facilitates various uses in research,” Carolyn Magill, Aetion CEO and board director, told MobiHealthNews.
Meanwhile, Aetion’s platform is focused on taking real-world data and making it into regulatory and decision-grade evidence that can inform stakeholders about the safety and effectiveness of clinical treatments and medications. Its clients include pharma manufacturers, health plans, payers and government agencies.
WHY IT MATTERS
The acquisition will give Aetion new capabilities in the synthetic real-world evidence space.
